Recommendations

Document Overview

Design and created by Guideline Central in participation with the Society of Gynecologic Oncology.

Hormone therapy (HT) in Women with Gynecologic Cancers and in Women at High Risk for Developing a Gynecologic Cancer

Society of Gynecologic Oncology

Publication Date: May 1, 2020

Page Last Updated: May 6, 2026

Document Overview

Document Title: Hormone therapy (HT) in Women with Gynecologic Cancers and in Women at High Risk for Developing a Gynecologic Cancer

Full Text Guideline: www.gynecologiconcology-online.net/article/S0090-8258(20)30088-3/pdf

Source Citation: Sinno AK, Pinkerton J, Febbraro T, Jones N, Khanna N, Temkin S, Iglesias D, Pothuri B. Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society. Gynecol Oncol. 2020 May;157(2):303-306. doi: 10.1016/j.ygyno.2020.01.035. Epub 2020 Feb 15. PMID: 32067815.

Diseases/Conditions (MeSH)

D006176 - Gynecology

Keywords: cervical cancer, chemotherapy, gynecologic cancers, hormone therapy

Intended Users: Nurse, Nurse Practitioner, Physician, Physician Assistant, Radiology Technologist

Hormone Therapy in Gynecologic Cancer Survivors
Uterine cancer
Early stage endometrial cancer	HT acceptable
Advanced stage endometrial cancer	HT not recommended
Uterine sarcoma	HT not recommended
Ovarian cancer
High grade serous ovarian cancer	HT acceptable
Low grade serous and endometrioid ovarian cancer	HT not recommended
Cervical cancer	HT acceptable
Hormone Therapy in Women at High Risk for Developing Gynecologic Cancer
BRCA mutation with no personal history of breast cancer	HT acceptable
BRCA mutation with personal history of breast cancer	HT not recommended
Lynch syndrome	HT acceptable